Origin Bancorp Inc【OBK】株式ニュース | ADVFN

US Dollar vs Yen

登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。

登録

ホーム
投資
株式
アメリカ
NYSE
Origin Bancorp Inc (OBK)
Origin Bancorp Inc (OBK) ニュース

Origin Bancorp Inc (OBK)

34.39

0.54

( 1.60% )

更新日時： 04:30:03

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 3 - Initial statement of beneficial ownership of securities

Origin Bancorp, Inc. Appoints Cecil Jones to Board of Directors

RUSTON, La., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Origin Bancorp, Inc. (NYSE: OBK) (“Origin”), the holding...

Form 8-K - Current report

Origin Bancorp, Inc. Reports Earnings For Third Quarter 2024

RUSTON, La., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Origin Bancorp, Inc. (NYSE: OBK) (“Origin,” “we,” “our” or the...

Origin Bancorp, Inc. Announces Declaration of Quarterly Cash Dividend

RUSTON, La., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Origin Bancorp, Inc. (NYSE: OBK) ("Origin"), the holding...

Form 8-K - Current report

Origin Bancorp, Inc. Announces Third Quarter 2024 Earnings Release and Conference Call

RUSTON, La., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Origin Bancorp, Inc. (NYSE: OBK) (“Origin”), the financial...

Form 8-K - Current report

Form 8-K - Current report

Origin Bancorp, Inc. Reports Earnings for Second Quarter 2024

RUSTON, La., July 24, 2024 (GLOBE NEWSWIRE) -- Origin Bancorp, Inc. (NYSE: OBK) (“Origin,” “we,” “our” or the...

manibiotech

manibiotech 3分前

However the data of current trial submitted for approval is not "in vitro"

payupdeadbeat

payupdeadbeat 3分前

It is clear that the "investment of a lifetime* message is not getting out. I hope the longs are not being hornscwaggled.

Craig305

Craig305 3分前

This is the highest day volume since June 2022.

Serpico2005

Serpico2005 4分前

HUGE revenue pouring in here, we won't be denied, won't be able the hold it down much longer.

delerious1

delerious1 4分前

Milling results soon yet some say that this stock is garbage etc have been here as long as me or longer so that would mean plenty of time to see the patterns and make some really good money....but I bet that they haven't....so it is a bit of a conundrum....why wouldn't they when obviously given the

ExtremelyBullishZig

ExtremelyBullishZig 4分前

No...all biotechs are up based on gene editing company success it move the index

richme

Need to Curb Your Enthusiasm just because the share price jumped all the way to $0.0166 share price,
-$0.0015 day change. Isn't that great? We will be heading to Mars soon....no less in Elon Musk's rocket ship or to hell in ________ (add your own).

Quintessence

Quintessence 4分前

PDYNW - Nice move today! I will consider buying dips.

JRoon71

JRoon71 4分前

TC, I get that. I just meant that in looking at what Italy pays for other drugs, what Amarin wants for Vazkepa is substantially more than MOST drugs on the list.

I'm not talking about the cost to patients, but the cost to the government.

If Vazkepa cost $15 to sell to

dennisdave

dennisdave 5分前

BTW, the three companies with approved PD1 inhibitors, which is what the U.S. patent office tried to narrow the combo patent to, are:

Merck = Keytruda

Opdivo = Bristol

Libtayo = Regeneron.
Thanks very helpful.

attilathehunt

attilathehunt 5分前

1 buy of 20k will work the same as 2 buys of 10k on squeeze day, no?

NO!!!!!

On squeeze day your first buy order will be much much lower than all subsequent ones...

For example, on Squeeze day (approval) if your first early open trade gets executed at 1.0

bgATL

Gaetz is out, my opinion has been he was never really going to be in the position, as it was cover to let him resign from the House before the severe reprimands which could have ruined his chances of a future career. Trump also could now argue he tried to put a pot friendly guy in the office and it

I wonder if .0011 is a good entry? Fishing time. 🎣

konshe

Strong buy at ask 0.0002, paint sell at bid 0.0001. 0.0002 2mm shares will be gone soon.

al44

The world will become safer when the ‘adults in the room’ are… gone

By Jack Hellner

When Biden and his team of incompetents took over, the media cheered that finally the adults were back in the room; well thankfully, the “children” will be back soon and the U.S.

Real McCoy

Real McCoy 5分前

I think they think that announced participation in a hot industry segment should entitle them to valuation levels of those hot industry segment leaders. Despite ALWAYS having virtually no revenue.

KRISGO

Hello Dcaf7, based on the full abstract being released on Nov 25th, can the experts evaluate whether same-day dosing is effective and works better?

PennyMillions852

PennyMillions852 5分前

BID building here but...you KNOW what will come next......this is the type of chit that needs to stop for us to move up above .0003!

Hitman970

Hitman970 6分前

Why hasn't this historic moment made any mainstream press?
x / twitter and company generate PRs mean nothing.
You are repeating yourself over and over. Do you know Vic? You called him "benign" a while back.

CrashOverride

CrashOverride 6分前

If it was DCVax the 2016 paper would cite Liau or Prins as they are the leaders in the field of Dendritic-cell-based vaccines.

They had several papers published before 2016.

It doesn't so it isn't DCVax.

biotechinvestor1

biotechinvestor1 6分前

From another poster: “Evotec has already said no thanks. Wall Street said no thanks. When Halozyme management says ok forget about it, we go up $10. We are waiting Ms Helen.”

BamaBreeze

BamaBreeze 6分前

Can you bring in the update your referencing(please).

redspinelpinktopaz

redspinelpinktopaz 6分前

No. It seems all right to me.

glenn1919

glenn1919 6分前

TRNR....CISO....MULN.........................https://stockcharts.com/h-sc/ui?s=MULN&p=D&yr=0&mn=2&dy=12&id=p84071410134

WinstonCup

WinstonCup 6分前

Sometimes you make no sense.

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約